González-Martín A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment, and follow-up. Ann Oncol. 2023;S0923–7534(23):00797–4. https://doi.org/10.1016/j.annonc.2023.07.011.

Article  CAS  Google Scholar 

González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–402. https://doi.org/10.1056/NEJMoa1910962.

Article  PubMed  Google Scholar 

Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–505. https://doi.org/10.1056/NEJMoa1810858.

Article  CAS  PubMed  Google Scholar 

• Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020;31(12):1606–1622. https://doi.org/10.1016/j.annonc.2020.08.2102. This reference is of importance as it outlines the European Society for Medical Oncology’s finalized recommendations for homologous recombination deficiency testing based on expert committee review of recently published literature and their strength of evidence.

Heeke AL, Pishvaian MJ, Lynce F, Xiu J, Brody JR, Chen WJ, et al. Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis Oncol. 2018;2:1–13.

Article  Google Scholar 

Beggs R, Yang ES. Targeting DNA repair in precision medicine. Adv Protein Chem Struct Biol. 2019;115:135–55.

Article  PubMed  Google Scholar 

Hopkins JL, Lan L, Zou L. DNA repair defects in cancer and therapeutic opportunities. Genes Dev. 2022;36(5–6):278–93. https://doi.org/10.1101/gad.349431.122.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pommier Y, O’Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016;8:362ps317.

Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:3785–90.

Article  CAS  Google Scholar 

Quesada S, Fabbro M, Solassol J. Toward more comprehensive homologous recombination deficiency assays in ovarian cancer, part 1: technical considerations. Cancers. 2022;14(5):1132. https://doi.org/10.3390/cancers14051132.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, et al. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2019;9(2):210–9. https://doi.org/10.1158/2159-8290.CD-18-0715.

Article  CAS  PubMed  Google Scholar 

Bernards SS, Pennington KP, Harrell MI, Agnew KJ, Garcia RL, Norquist BM, Swisher EM. Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma. Gynecol Oncol. 2018;148(2):281–5. https://doi.org/10.1016/j.ygyno.2017.12.004.

Article  CAS  PubMed  Google Scholar 

Takaya H, Nakai H, Takamatsu S, Mandai M, Matsumura N. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Sci Rep. 2020;10(1):2757. https://doi.org/10.1038/s41598-020-59671-3.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Alldredge J, Randall L. Germline and somatic tumor testing in gynecologic cancer care. Obstet Gynecol Clin North Am. 2019;46(1):37–53.

Article  PubMed  PubMed Central  Google Scholar 

Ewing A, Meynert A, Churchman M, Grimes GR, Hollis RL, C. Simon Herrington, et al. Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high-grade serous ovarian carcinoma. Clin Can Res. 2021;27(11):3201–14.

Mangogna A, Munari G, Pepe F, Maffii E, Giampaolino P, Ricci G, et al. Homologous recombination deficiency in ovarian cancer: from the biological rationale to current diagnostic approaches. J of Pers Med. 2023 Feb 1;13(2):284. Available from: https://www.mdpi.com/2075-4426/13/2/284.

Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20:764–75.

Article  CAS  PubMed  Google Scholar 

Toh M, Ngeow J. Homologous recombination deficiency: cancer predispositions and treatment implications. Oncologist. 2021;26(9).

• Kalachand RD, Stordal B, Madden S, Chandler B, Cunningham J, Goode EL, et al. BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2020;112:1190–1203. This reference is of importance because it evaluates methodological and mechanistic differences in BRCA methylation assays that may be contributing to heterogeneous results noted in prior studies.

The Cancer Genome Atlas (TCGA) Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474: 609−15.

Baldwin AL, Cook-Deegan R. Constructing narratives of heroism and villainy: case study of Myriad’s BRACAnalysis((R)) compared to Genentech’s Herceptin((R)). Genome Med. 2013;5:8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nelson HD, Pappas M, Cantor A, Haney E, Holmes R. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2019;322:666–85.

Article  PubMed  Google Scholar 

BRACAnalysis CDx ® Technical Information. Available from: https://s3.amazonaws.com/myriad-web/BRACAnalysisCDxTS.pdf.

Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat. 2018;39:593–620.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ellison G, Ahdesmaki MJ, Luke S, Waring P, Wallace A, Wright R, et al. An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice. Hum Mutat. 2017;39(3):394–405.

Article  PubMed  PubMed Central  Google Scholar 

Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016;140(2):199–203. https://doi.org/10.1016/j.ygyno.2015.12.020.

Article  CAS  PubMed  Google Scholar 

•• Mohyuddin GR, Aziz M, Britt A, Wade L, Sun W, Baranda J, et al. Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus germline BRCA mutations: a meta-analysis and systematic review. BMC Cancer. 2020;20(1):507. https://doi.org/10.1186/s12885-020-06948-5. This reference is of great importance as it provides a systematic review and meta-analysis of major PARPi trials in the past decade and analyses differences in outcomes between germline and somatic BRCA mutation status.

Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87. https://doi.org/10.1016/S1470-2045(16)30559-9.

Article  CAS  PubMed  Google Scholar 

Sokol ES, Pavlick D, Khiabanian H, Frampton GM, Ross JS, Gregg JP, et al. Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity. JCO Precis Oncol. 2020;4:442–65.

Article  PubMed  Google Scholar 

Ngoi NYL, Tan DSP. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it? ESMO Open. 2021;6(3): 100144.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu CC, Qiu W, Juang CS, Mansukhani MM, Halmos B, Su GH. Mutant allele specific imbalance in oncogenes with copy number alterations: occurrence, mechanisms, and potential clinical implications. Cancer Lett. 2017;384:86–93.

Article  CAS  PubMed  Google Scholar 

Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107:1776–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012;2:366–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mills GB, Timms KM, Reid JE, Gutin AS, Krivak TC, Hennessy B, et al. Homologous recombination deficiency score shows superior association with outcome compared with its individual score components in platinum-treated serous ovarian cancer. Gynecol Oncol. 2016;141:2–3.

Article  Google Scholar 

Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, et al. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 2014;16:475.

Article  PubMed  PubMed Central  Google Scholar 

Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22:3764–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Fumagalli C, Betella I, Ranghiero A, Guerini-Rocco E, Bonaldo G, Rappa A, et al. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus Panel with Myriad MyChoiceCDx Assay. Pathologica. 2022;114:288–294. This reference is of importance because it provides both study design and outcomes for a decentralized HRD testing alternative to FDA-approved genomic scar assays.

Buisson A, Saintigny P, Pujade-Lauraine E, Montoto-Grillot C, Vacirca D, Barberis M, et al. A deep learning solution for detection of homologous recombination deficiency in ovarian cancer using low pass-whole genome sequencing: evaluation of analytical performance. J Clin Oncol. 2022;40:16_suppl:e17599–e17599. https://doi.org/10.1200/JCO.2022.40.16_suppl.e17599.

Doig KD, Fellowes AP, Fox SB. Homologous recombination repair deficiency: an overview for pathologists. Mod Pathol. 2023;36(3): 100049. https://doi.org/10.1016/j.modpat.2022.100049.

Article  PubMed  Google Scholar 

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21. https://doi.org/10.1200/JCO.2022.40.16_suppl.e1759910.1038/nature12477.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cosmic. COSMIC. Sanger.ac.uk. COSMIC; 2019. Available from: https://cancer.sanger.ac.uk/cosmic.

Gulhan DC, Lee JJ, Melloni GEM, Cortés-Ciriano I, Park PJ. Detecting the mutational signature of homologous recombination deficiency in clinical samples. Nat Genet. 2019;51(5):912–9. https://doi.org/10.1038/s41588-019-0390-2.

Article  CAS  PubMed